Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C CAR 088

Next Previous
Search
Drug Profile

C CAR 088

Alternative Names: Anti BCMA CAR T Cell Therapy - AbelZeta Pharma; BCMA-directed CAR-T Cells - AbelZeta Pharma; C-CAR088; CBM.BCMA Chimeric Antigen Receptor T cell

Latest Information Update: 27 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group
  • Developer AbelZeta Pharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
  • 25 Aug 2022 C CAR 088 is still in phase-I development in Multiple-myeloma (Second-line therapy or greater) in China (IV, Infusion) (Cellular Biomedicine Group pipeline, August 2022)
  • 14 Jul 2022 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in China (unspecified route) (NCT05632380)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top